[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Activbody, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":56},{"warningLetters":4,"total":55},[5,32],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},2604,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-06-28T13:20:00Z\">06\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-27T04:00:00Z\">05\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fre-gen-active-lab-inc-620763-05272022\">Re-Gen Active Lab, Inc.\u003C\u002Fa>","Office of Biological Products Operations – Division 2","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)\u003Cbr \u002F>\r\n","","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Martin M. Porter\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Re-Gen Active Lab, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2216 W. Walnut Hill Lane\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irving\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75038\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 27, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter #OBPO 22-620763\u003C\u002Fstrong>\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Porter:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Re-Gen Active Lab, Inc. (Re-Gen Active Lab), located at 2216 W. Walnut Hill Lane, Irving, TX 75038, conducted between July 19, 2021 and July 28, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of cellular products for allogeneic use, namely, an amniotic membrane derived cellular product, ActiveFlow™, a human umbilical cord tissue derived cellular product, ActiveShot™, and a cellular product derived from both human umbilical cord tissue and amniotic membrane, ActivePro™ (collectively, “your products”). You have distributed your products directly to a third-party distributor, physicians, and medical clinics throughout the United States. These products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to, during, and\u002For after the inspection, including information on your website, regenactivelab.com, reflect your products are intended to treat various diseases or conditions. Therefore, your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Re-Gen Active Lab does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FPs derived from umbilical cord and\u002For amniotic membrane fail to meet all the criteria in 21 CFR 1271.10(a). Therefore, your products are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>Specifically, your products fail to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FPs be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent.” Your products are not intended to perform the same basic function or functions of umbilical cord or amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord); or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Using your products for orthopedic diseases or conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>In addition, your products fail to meet other criteria set forth in 21 CFR 1271.10(a). Your products derived from umbilical cord (ActiveShotTM), amniotic membrane (ActiveFlowTM), and both umbilical cord and amniotic membrane (ActiveProTM) fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord and\u002For amniotic membrane related to their utility for reconstruction, repair, or replacement.\u003C\u002Fp>\n\n\u003Cp>Be advised that to lawfully market a drug that is a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA) nor is there an IND in effect for any of them. Based on this information, your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the July 2021 inspection, as discussed below.\u003C\u002Fp>\n\n\u003Cp>The CGMP deviations, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of products manufactured between \u003Cstrong>(b)(4)\u003C\u002Fstrong>, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of the aseptic process [21 CFR 211.113(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You failed to validate the aseptic processes used to manufacture ActiveShot™, ActivePro™, and ActiveFlow™ (i.e., by performing media fill simulations) since product manufacturing began in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. At the time of the inspection, FDA investigators observed personnel practices that do not adequately protect against microbiological contamination of your products, including the use of non-sterile protective equipment (PPE) such as face masks, beard covers, foot covers, and hair nets, worn by your employees during the aseptic processing of your products.\u003C\u002Fp>\n\n\u003Cp>c. You have not established appropriate written procedures for environmental, including personnel, monitoring in the aseptic processing areas where your products are manufactured. Specifically:\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; i. You have not performed routine microbiological monitoring of the air, critical surfaces, and personnel in the aseptic processing area.\u003Cbr>\n&nbsp; &nbsp; ii. You have not performed routine non-viable particulate monitoring of the critical area (i.e., inside the laminar flow hood (LFH) where your products are exposed to the environment).\u003Cbr>\n&nbsp; &nbsp; iii. You have not performed non-viable particulate monitoring of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> on a sufficient frequency to demonstrate control of the aseptic processing area during manufacturing. Additionally, you have not established alert or action limits for particulate monitoring of the \u003Cstrong>(b)(4)\u003Csup>\u003Cem>1\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to routinely calibrate, inspect or check automatic, mechanical or electronic equipment or other types of equipment, including computers, or related systems that will perform a function satisfactorily, that are used in the manufacture, processing, packing and holding of a drug product, according to a written program designed to assure proper performance [21 CFR 211.68(a)].\u003C\u002Fstrong> Specifically, you have failed to routinely calibrate, inspect or check (e.g., certify) the LFH where your products are exposed to the environment during aseptic processing.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>3. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [21 CFR 211.67(b)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>a. You have not validated your process for cleaning and disinfecting the LFH, the critical aseptic processing area where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>b. At the time of the inspection, your written procedure for the cleaning and disinfecting the LFH did not include a description in sufficient detail of the methods, equipment, and materials used in cleaning and maintenance operations. Specifically, the written procedure was found lacking adequate instructions, including information about cleaning agents that must be used, required contact times for disinfectants, and use of a sporicidal agent.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish written procedures describing in sufficient detail the cleaning methods, equipment, and materials to be used in cleaning the buildings and facilities [21 CFR 211.56(b)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>a. You have not validated the process for cleaning and disinfecting your \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>b. At the time of the inspection, your written procedure for cleaning and disinfection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was inadequate in that it did not include a description in sufficient detail of the cleaning schedules, methods, equipment, and materials to be used in cleaning the facility. Specifically, the written procedure lacked adequate instructions, including cleaning agents used, contact times for disinfectants, and use of a sporicidal agent.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. \u003C\u002Fstrong>For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not validated the manufacturing processes for ActiveShot™, ActivePro™, and ActiveFlow™ with respect to identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>b. You have not established written procedures that describe the manufacture of ActivePro™, which was described to FDA investigators during the inspection as being manufactured from ActiveShot™ and ActiveFlow™ final bulk products. You also have not established written procedures that describe the manufacturing step involving controlled rate freezing of ActivePro™, ActiveShot™, and ActiveFlow™ in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to satisfy general biological products standards for sterility testing [21 CFR 610.12].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not validated your in-house sterility test method used to demonstrate your method is capable of reliably and consistently detecting the presence of viable contaminating microorganisms in products. This also represents a failure to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods you employ, as required by 21 CFR 211.165(e).\u003C\u002Fp>\n\n\u003Cp>b. Your written procedure for sterility testing does not include details regarding the composition of the culture media to be used, growth-promotion test requirements, and the number and volume of articles to be tested.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish and follow written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, approval or rejection of components and drug product containers and closures [21 CFR 211.80(a)].\u003C\u002Fstrong> Specifically, your firm lacks written procedures describing in sufficient detail the criteria for approval or rejection of incoming human umbilical cord tissue, amniotic membrane, other components, and drug product containers and closures.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, you assign a two-year expiration date to your products without supporting data.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)].\u003C\u002Fstrong> Specifically, your batch production records do not include documentation of the accomplishment of each significant step in the manufacture of your products or the person(s) performing each of those steps.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your correspondence dated August 12, 2021, which provides a response to FDA’s inspectional observations (FDA-483) and describes certain corrective actions. We have reviewed your response and represented corrective actions and have found that they are inadequate. Your response does not include sufficient detail for FDA to fully assess the adequacy of your corrective actions; it lacks documentation to demonstrate that you have corrected your violations and fails to include a timeline for completion of all necessary corrective actions. For example, while you have represented that you have corrected various deficiencies (e.g., you represent that you have written environmental monitoring procedures), you have not provided documentation of your corrective actions for our review. FDA will need to verify and evaluate any corrective actions during a reinspection of your firm.\u003C\u002Fp>\n\n\u003Cp>Additionally, you stated during the inspection that you ceased manufacturing your products in October 2020 due to the COVID-19 pandemic. However, you have distributed your product after this date, most recently in July 2021. Your written response did not include a discussion about your plans to continue manufacturing your umbilical cord derived and\u002For amniotic membrane derived products.\u003C\u002Fp>\n\n\u003Cp>Your response also does not address the quantity of product inventory you may still have at your facility and your plans for its disposition. Furthermore, your response does not describe actions you have taken or plan to take to address the impact of the above-described CGMP deficiencies on your distributed products that carry a two-year shelf life and remain within expiry.\u003C\u002Fp>\n\n\u003Cp>Importantly, your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, in order to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an IND in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA 483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure that your establishment is in full compliance with the law.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include any documentation necessary to show that correction has been achieved. If you believe that your products are not in violation of the FD&amp;C Act, the PHS Act, and applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 271-1242 x 104 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>Cc: Deepesh Shrestha, President\u002FChief Financial Officer\u003Cbr>\nRe-Gen Active Lab, Inc.\u003Cbr>\n2216 W. Walnut Hill Ln.\u003Cbr>\nIrving, TX 75038\u003C\u002Fp>\n\n\u003Cp>Cc: Sagar Nepal, Chief Scientific Officer\u003Cbr>\nRe-Gen Active Lab, Inc.\u003Cbr>\n2216 W. Walnut Hill Ln.\u003Cbr>\nIrving, TX 75038\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\">https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\u003C\u002Fa>. FDA’s guidance documents do not establish legal requirements.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMartin M. Porter\n\nRecipient Title\n\nChief Operating Officer\n\nRe-Gen Active Lab, Inc.\n\n2216 W. Walnut Hill Lane\n\nIrving, TX 75038\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division 2\n\nUnited States\n\nWARNING LETTER\n\nMay 27, 2022\n\nWarning Letter #OBPO 22-620763\n\nDear Mr. Porter:\n\nDuring an inspection of your firm, Re-Gen Active Lab, Inc. (Re-Gen Active Lab), located at 2216 W. Walnut Hill Lane, Irving, TX 75038, conducted between July 19, 2021 and July 28, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of cellular products for allogeneic use, namely, an amniotic membrane derived cellular product, ActiveFlow™, a human umbilical cord tissue derived cellular product, ActiveShot™, and a cellular product derived from both human umbilical cord tissue and amniotic membrane, ActivePro™ (collectively, “your products”). You have distributed your products directly to a third-party distributor, physicians, and medical clinics throughout the United States. These products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to, during, and\u002For after the inspection, including information on your website, regenactivelab.com, reflect your products are intended to treat various diseases or conditions. Therefore, your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nRe-Gen Active Lab does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FPs derived from umbilical cord and\u002For amniotic membrane fail to meet all the criteria in 21 CFR 1271.10(a). Therefore, your products are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nSpecifically, your products fail to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FPs be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent.” Your products are not intended to perform the same basic function or functions of umbilical cord or amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord); or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Using your products for orthopedic diseases or conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\n\nIn addition, your products fail to meet other criteria set forth in 21 CFR 1271.10(a). Your products derived from umbilical cord (ActiveShotTM), amniotic membrane (ActiveFlowTM), and both umbilical cord and amniotic membrane (ActiveProTM) fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord and\u002For amniotic membrane related to their utility for reconstruction, repair, or replacement.\n\nBe advised that to lawfully market a drug that is a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved biologics license application (BLA) nor is there an IND in effect for any of them. Based on this information, your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the July 2021 inspection, as discussed below.\n\nThe CGMP deviations, involving over (b)(4) vials of products manufactured between (b)(4), include, but are not limited to, the following:\n\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of the aseptic process [21 CFR 211.113(b)]. For example:\n\na. You failed to validate the aseptic processes used to manufacture ActiveShot™, ActivePro™, and ActiveFlow™ (i.e., by performing media fill simulations) since product manufacturing began in (b)(4). Your products purport to be sterile and are expected to be sterile.\n\nb. At the time of the inspection, FDA investigators observed personnel practices that do not adequately protect against microbiological contamination of your products, including the use of non-sterile protective equipment (PPE) such as face masks, beard covers, foot covers, and hair nets, worn by your employees during the aseptic processing of your products.\n\nc. You have not established appropriate written procedures for environmental, including personnel, monitoring in the aseptic processing areas where your products are manufactured. Specifically:\n\ni. You have not performed routine microbiological monitoring of the air, critical surfaces, and personnel in the aseptic processing area.\n\nii. You have not performed routine non-viable particulate monitoring of the critical area (i.e., inside the laminar flow hood (LFH) where your products are exposed to the environment).\n\niii. You have not performed non-viable particulate monitoring of the (b)(4) on a sufficient frequency to demonstrate control of the aseptic processing area during manufacturing. Additionally, you have not established alert or action limits for particulate monitoring of the (b)(4)1.\n\n2. Failure to routinely calibrate, inspect or check automatic, mechanical or electronic equipment or other types of equipment, including computers, or related systems that will perform a function satisfactorily, that are used in the manufacture, processing, packing and holding of a drug product, according to a written program designed to assure proper performance [21 CFR 211.68(a)]. Specifically, you have failed to routinely calibrate, inspect or check (e.g., certify) the LFH where your products are exposed to the environment during aseptic processing.\n\n3. Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [21 CFR 211.67(b)].\n\na. You have not validated your process for cleaning and disinfecting the LFH, the critical aseptic processing area where your products are manufactured.\n\nb. At the time of the inspection, your written procedure for the cleaning and disinfecting the LFH did not include a description in sufficient detail of the methods, equipment, and materials used in cleaning and maintenance operations. Specifically, the written procedure was found lacking adequate instructions, including information about cleaning agents that must be used, required contact times for disinfectants, and use of a sporicidal agent.\n\n4. Failure to establish written procedures describing in sufficient detail the cleaning methods, equipment, and materials to be used in cleaning the buildings and facilities [21 CFR 211.56(b)].\n\na. You have not validated the process for cleaning and disinfecting your (b)(4).\n\nb. At the time of the inspection, your written procedure for cleaning and disinfection of (b)(4) was inadequate in that it did not include a description in sufficient detail of the cleaning schedules, methods, equipment, and materials to be used in cleaning the facility. Specifically, the written procedure lacked adequate instructions, including cleaning agents used, contact times for disinfectants, and use of a sporicidal agent.\n\n5. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example:\n\na. You have not validated the manufacturing processes for ActiveShot™, ActivePro™, and ActiveFlow™ with respect to identity, strength, quality, and purity.\n\nb. You have not established written procedures that describe the manufacture of ActivePro™, which was described to FDA investigators during the inspection as being manufactured from ActiveShot™ and ActiveFlow™ final bulk products. You also have not established written procedures that describe the manufacturing step involving controlled rate freezing of ActivePro™, ActiveShot™, and ActiveFlow™ in (b)(4).\n\n6. Failure to satisfy general biological products standards for sterility testing [21 CFR 610.12]. For example:\n\na. You have not validated your in-house sterility test method used to demonstrate your method is capable of reliably and consistently detecting the presence of viable contaminating microorganisms in products. This also represents a failure to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods you employ, as required by 21 CFR 211.165(e).\n\nb. Your written procedure for sterility testing does not include details regarding the composition of the culture media to be used, growth-promotion test requirements, and the number and volume of articles to be tested.\n\n7. Failure to establish and follow written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, approval or rejection of components and drug product containers and closures [21 CFR 211.80(a)]. Specifically, your firm lacks written procedures describing in sufficient detail the criteria for approval or rejection of incoming human umbilical cord tissue, amniotic membrane, other components, and drug product containers and closures.\n\n8. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, you assign a two-year expiration date to your products without supporting data.\n\n9. Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)]. Specifically, your batch production records do not include documentation of the accomplishment of each significant step in the manufacture of your products or the person(s) performing each of those steps.\n\nWe acknowledge receipt of your correspondence dated August 12, 2021, which provides a response to FDA’s inspectional observations (FDA-483) and describes certain corrective actions. We have reviewed your response and represented corrective actions and have found that they are inadequate. Your response does not include sufficient detail for FDA to fully assess the adequacy of your corrective actions; it lacks documentation to demonstrate that you have corrected your violations and fails to include a timeline for completion of all necessary corrective actions. For example, while you have represented that you have corrected various deficiencies (e.g., you represent that you have written environmental monitoring procedures), you have not provided documentation of your corrective actions for our review. FDA will need to verify and evaluate any corrective actions during a reinspection of your firm.\n\nAdditionally, you stated during the inspection that you ceased manufacturing your products in October 2020 due to the COVID-19 pandemic. However, you have distributed your product after this date, most recently in July 2021. Your written response did not include a discussion about your plans to continue manufacturing your umbilical cord derived and\u002For amniotic membrane derived products.\n\nYour response also does not address the quantity of product inventory you may still have at your facility and your plans for its disposition. Furthermore, your response does not describe actions you have taken or plan to take to address the impact of the above-described CGMP deficiencies on your distributed products that carry a two-year shelf life and remain within expiry.\n\nImportantly, your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, in order to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an IND in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nNeither this letter nor the observations noted on the Form FDA 483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure that your establishment is in full compliance with the law.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include any documentation necessary to show that correction has been achieved. If you believe that your products are not in violation of the FD&C Act, the PHS Act, and applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\n\nYour response should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 271-1242 x 104 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\nCc: Deepesh Shrestha, President\u002FChief Financial Officer\n\nRe-Gen Active Lab, Inc.\n\n2216 W. Walnut Hill Ln.\n\nIrving, TX 75038\n\nCc: Sagar Nepal, Chief Scientific Officer\n\nRe-Gen Active Lab, Inc.\n\n2216 W. Walnut Hill Ln.\n\nIrving, TX 75038\n\n_____________________\n\n1 For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf. FDA’s guidance documents do not establish legal requirements.","Re-Gen Active Lab, Inc.","re-gen-active-lab-inc-620763-05272022","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fre-gen-active-lab-inc-620763-05272022","2026-10-26T08:09:47.67412+00:00","Warning Letter","Issued","2022-06-28","620763","Biologics","Martin M. Porter","2026-08-20T01:49:17.56+00:00","VIA UNITED PARCEL SERVICE","2022-05-27",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":20,"letter_url":45,"updated_at":46,"action_type":23,"case_status":24,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":20,"reference_number":53,"action_taken_date":54,"medical_device_id":20,"response_letter_date":20},183,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2026-05-05T04:00:00Z\">05\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-22T04:00:00Z\">04\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Factive-cosmetics-manufacturing-inc-722408-04222026\">Active Cosmetics Manufacturing Inc. \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-71\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Celia Ferreira\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Active Cosmetics Manufacturing Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7075 Kingspointe Parkway, Suites 2, 3, 4, and 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Orlando\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32819-6540\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-71\u003C\u002Fp>\u003Cp>April 22, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Ferreira:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Active Cosmetics Manufacturing Inc., FEI 3005351079, at 7075 Kingspointe Parkway, Suites 2, 3, 4, and 5, Orlando, from October 27 to 31, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 21, 2025 response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture topical over-the-counter (OTC) drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> labeled for use in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You failed to adequately investigate out-of-specification (OOS) microbiological test results of your drug products.\u003C\u002Fp>\u003Cp>You released batches for commercial distribution based on passing retest results, without conducting thorough investigations to determine the root causes of the original results. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> was found to contain the objectionable microorganism \u003Cem>Staphylococcus aureus\u003C\u002Fem>.\u003C\u002Fli>\u003Cli>Batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> was found to contain the objectionable microorganism \u003Cem>Pseudomonas aeruginosa\u003C\u002Fem>.\u003C\u002Fli>\u003Cli>Batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed the Neogen Soleris Next Generation System test that you claimed assesses total viable count.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Passing retest results alone cannot serve as the basis for invalidating OOS results. As a manufacturer, you have a responsibility to fully investigate aberrant microbial test results that may impact drug product quality. In addition, investigations into microbial contamination should include awareness that microbial contamination is not uniformly distributed.\u003C\u002Fp>\u003Cp>These findings are indicative of a lack of state of control of your manufacturing processes. We note that your firm has not performed process validation studies to determine whether the processes used to produce your marketed OTC drugs are reliable and reproducible.\u003C\u002Fp>\u003Cp>In your response, you state you retested reserve samples from affected batches and initiated an investigation. You also revised your OOS procedure to include more detailed guidance on phase I and II investigations, root cause determination, and to assess impact on other batches and procedures.\u003C\u002Fp>\u003Cp>Your response is inadequate because it lacks a systemic investigation into the root cause of the OOS microbial results. Additionally, your response lacks a comprehensive drug product impact assessment that accounts for potentially impacted drug products within expiry.\u003C\u002Fp>\u003Cp>It is essential to conduct thorough, well documented, and scientifically sound investigations to identify root causes of OOS results, evaluate all potentially affected batches, and implement timely and effective corrective action and preventive action (CAPA) plans.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Revised OOS investigation procedures with these and other remediations\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing PPQ for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocols, and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately validate your alternative rapid microbiological test methods. You use the Neogen Soleris Next Generation System for rapid microbiological testing of your finished drug products (e.g., total aerobic counts, total counts, specified microorganisms) and failed to demonstrate that it was equivalent to or better than United States Pharmacopeia (USP) compendial methods and suitable for its intended use.\u003C\u002Fp>\u003Cp>You stated that this system was validated by the manufacturer. However, your method did not meet the minimum requirements for adequate identification of objectionable microorganisms and total count quantification.\u003C\u002Fp>\u003Cp>The microbiological testing methodology uses qualitative pass\u002Ffail criteria that do not ensure appropriate quantitative enumeration. The method is inadequate because it does not provide sufficient data on contamination levels, which are essential for trend analysis and evidence-based risk assessment to support quality evaluations and patient safety.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that you have not validated your alternative rapid microbiological test methods. You state you will fully validate methods used in your alternative rapid microbiological testing within six to eight months.\u003C\u002Fp>\u003Cp>Your response is inadequate because it fails to address the fundamental gap between qualitative pass\u002Ffail criteria and appropriate quantitative enumeration.\u003C\u002Fp>\u003Cp>Test methods must be validated to show that they are suitable for their intended use and equivalent to or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine whether your drug products meet established specifications for microbial attributes.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A comprehensive independent evaluation of microbiological tests methods used to perform total counts and identification to evaluate suitability for intended use, followed by systemic CAPA including, but not limited to:\u003Cbr>o A comprehensive retrospective evaluation of each test method to determine any inadequacies including, but not limited to, those cited in this letter.\u003Cbr>o Where a method is found unsuitable for its intended use (e.g., inadequate capacity to accurately enumerate, microbial identification), provide information on a new suitable method that will be employed.\u003Cbr>o Improved systems to ensure suitability of microbiological test methods in the future before implementation.\u003Cbr>o Once this full evaluation is complete, provide a summary of findings, data, and all deviations encountered.\u003C\u002Fli>\u003Cli>Following review by an independent third-party, provide updated validation protocols and final reports that adequately address methods for each product, including specificity, limit of detection, robustness, ruggedness, and repeatability. This should also include an evaluation of whether sample sizes are appropriate. Where you intend to use non-compendial methods, provide studies evaluating the equivalence or superiority of the method to the USP method.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed in the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to perform adequate identity testing on each shipment of each lot of incoming components (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) used in the manufacture of your drug products. In addition, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of each of your component suppliers’ analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to adequately test each shipment of each lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which you used as inactive ingredients in your drug products, for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. Complete identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain other high-risk drug components includes a limit test in the USP to ensure that the component meets the relevant safety limits for levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination at \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your response, you state that you have conducted a retrospective analysis and intend to have a qualified independent laboratory perform additional analysis. However, you fail to show that the retrospective testing meets full USP compendial requirements for ingredients at high risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. You also fail to show that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> you tested from your current inventory are fully representative of the component lots you used in your drug products that remain within expiry.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have assurance that components conform to appropriate specifications prior to use in the drug products you manufacture. As a manufacturer, you have the responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data)\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systemic CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. We note that under section 301(a) of the FD&amp;C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>We also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&amp;C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>After you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005351079 and ATTN: Rokhsana Safaai-Jazi.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nReference #:\n\n320-26-71\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Celia Ferreira\n\nRecipient Title\n\nCEO\n\nActive Cosmetics Manufacturing Inc.\n\n7075 Kingspointe Parkway, Suites 2, 3, 4, and 5\n\nOrlando, FL 32819-6540\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-71\nApril 22, 2026\nDear Ms. Ferreira:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Active Cosmetics Manufacturing Inc., FEI 3005351079, at 7075 Kingspointe Parkway, Suites 2, 3, 4, and 5, Orlando, from October 27 to 31, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 21, 2025 response to our Form FDA 483 in detail.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYou manufacture topical over-the-counter (OTC) drug products, including (b)(4) labeled for use in (b)(4). You failed to adequately investigate out-of-specification (OOS) microbiological test results of your drug products.\nYou released batches for commercial distribution based on passing retest results, without conducting thorough investigations to determine the root causes of the original results. For example:\nBatch (b)(4) was found to contain the objectionable microorganism Staphylococcus aureus.\nBatch (b)(4) was found to contain the objectionable microorganism Pseudomonas aeruginosa.\nBatch (b)(4) failed the Neogen Soleris Next Generation System test that you claimed assesses total viable count.\nPassing retest results alone cannot serve as the basis for invalidating OOS results. As a manufacturer, you have a responsibility to fully investigate aberrant microbial test results that may impact drug product quality. In addition, investigations into microbial contamination should include awareness that microbial contamination is not uniformly distributed.\nThese findings are indicative of a lack of state of control of your manufacturing processes. We note that your firm has not performed process validation studies to determine whether the processes used to produce your marketed OTC drugs are reliable and reproducible.\nIn your response, you state you retested reserve samples from affected batches and initiated an investigation. You also revised your OOS procedure to include more detailed guidance on phase I and II investigations, root cause determination, and to assess impact on other batches and procedures.\nYour response is inadequate because it lacks a systemic investigation into the root cause of the OOS microbial results. Additionally, your response lacks a comprehensive drug product impact assessment that accounts for potentially impacted drug products within expiry.\nIt is essential to conduct thorough, well documented, and scientifically sound investigations to identify root causes of OOS results, evaluate all potentially affected batches, and implement timely and effective corrective action and preventive action (CAPA) plans.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequate scoping of each investigation and its CAPA\no Revised OOS investigation procedures with these and other remediations\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing PPQ for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocols, and written procedures for qualification of equipment and facilities.\n2. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\nYou failed to adequately validate your alternative rapid microbiological test methods. You use the Neogen Soleris Next Generation System for rapid microbiological testing of your finished drug products (e.g., total aerobic counts, total counts, specified microorganisms) and failed to demonstrate that it was equivalent to or better than United States Pharmacopeia (USP) compendial methods and suitable for its intended use.\nYou stated that this system was validated by the manufacturer. However, your method did not meet the minimum requirements for adequate identification of objectionable microorganisms and total count quantification.\nThe microbiological testing methodology uses qualitative pass\u002Ffail criteria that do not ensure appropriate quantitative enumeration. The method is inadequate because it does not provide sufficient data on contamination levels, which are essential for trend analysis and evidence-based risk assessment to support quality evaluations and patient safety.\nIn your response, you acknowledge that you have not validated your alternative rapid microbiological test methods. You state you will fully validate methods used in your alternative rapid microbiological testing within six to eight months.\nYour response is inadequate because it fails to address the fundamental gap between qualitative pass\u002Ffail criteria and appropriate quantitative enumeration.\nTest methods must be validated to show that they are suitable for their intended use and equivalent to or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine whether your drug products meet established specifications for microbial attributes.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA comprehensive independent evaluation of microbiological tests methods used to perform total counts and identification to evaluate suitability for intended use, followed by systemic CAPA including, but not limited to:\no A comprehensive retrospective evaluation of each test method to determine any inadequacies including, but not limited to, those cited in this letter.\no Where a method is found unsuitable for its intended use (e.g., inadequate capacity to accurately enumerate, microbial identification), provide information on a new suitable method that will be employed.\no Improved systems to ensure suitability of microbiological test methods in the future before implementation.\no Once this full evaluation is complete, provide a summary of findings, data, and all deviations encountered.\nFollowing review by an independent third-party, provide updated validation protocols and final reports that adequately address methods for each product, including specificity, limit of detection, robustness, ruggedness, and repeatability. This should also include an evaluation of whether sample sizes are appropriate. Where you intend to use non-compendial methods, provide studies evaluating the equivalence or superiority of the method to the USP method.\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed in the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou failed to perform adequate identity testing on each shipment of each lot of incoming components (e.g., (b)(4)) used in the manufacture of your drug products. In addition, you relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of each of your component suppliers’ analyses at appropriate intervals.\n(b)(4)\nYou failed to adequately test each shipment of each lot of (b)(4), which you used as inactive ingredients in your drug products, for (b)(4) contamination. Complete identity testing for (b)(4), and certain other high-risk drug components includes a limit test in the USP to ensure that the component meets the relevant safety limits for levels of (b)(4). Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for (b)(4) contamination at (b)(4).\nIn your response, you state that you have conducted a retrospective analysis and intend to have a qualified independent laboratory perform additional analysis. However, you fail to show that the retrospective testing meets full USP compendial requirements for ingredients at high risk for (b)(4) contamination. You also fail to show that the (b)(4) you tested from your current inventory are fully representative of the component lots you used in your drug products that remain within expiry.\nWithout adequate testing, you do not have assurance that components conform to appropriate specifications prior to use in the drug products you manufacture. As a manufacturer, you have the responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\no an assessment of all materials to determine whether they are consistently of acceptable quality\no a review to ensure assigned expiration or retest dates are appropriate (supported by data)\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\nBased on a thorough review, provide a summary of your systemic CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\nA commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination (including, but not limited to, (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act (21 U.S.C. 321(i)). Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. We note that under section 301(a) of the FD&C Act (21 U.S.C. 331(a)), it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nWe also note that the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) provides new requirements with which facilities that manufacture cosmetic products must comply. You may find the FD&C Act, MoCRA, and FDA’s regulations through links on FDA’s website at www.fda.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nAfter you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3005351079 and ATTN: Rokhsana Safaai-Jazi.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Active Cosmetics Manufacturing Inc.","active-cosmetics-manufacturing-inc-722408-04222026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Factive-cosmetics-manufacturing-inc-722408-04222026","2026-10-26T08:07:49.865485+00:00","2026-05-05","722408","Drugs","Ms. Celia Ferreira","2026-08-19T04:43:26.19+00:00","Via Electronic Mail - Return Receipt Requested","320-26-71","2026-04-22",2,{"510k":57,"classification":58,"enforcement":59,"event":60,"event_backfill":61,"pma":62,"warning_letter":63},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]